BioSpace News Archive

The shares commenced trading on the NASDAQ Global Select Market on January 26, 2018 under the ticker symbol “TORC.”

The NDA submission is based on a comprehensive clinical efficacy and safety package with data from more than 30 clinical trials and more than 1,500 patients with MDD.

The conference is organised by the Cholangiocarcinoma Foundation and will be held from 31 January to 2 February 2018.

QIAGEN N.V. announced results of operations for the fourth quarter and full-year 2017, delivering on goals for adjusted net sales and adjusted earnings per share while driving the global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.

All the shares sold in the offering were offered by Synlogic.

Total CF product revenues increased 29% to $2.17 billion from $1.68 billion for 2016.

Incyte announced today an update to the conference call and webcast time for its fourth quarter and year end 2017 financial results to 8:00 a.m. ET on Thursday, February 15, 2018.

Electromed announced that it will issue its financial results press release for the fiscal 2018 second quarter ended December 31, 2017 on Tuesday, February 13, 2018 after the close of the stock market.

The following is a statement from Wouter Latour, M.D., Chief Executive Officer of Vaxart, who will lead the combined company following completion of the transaction:

Vaxart announced today that its investigational H1 influenza oral tablet vaccine demonstrated a statistically significant reduction in the rate of influenza infection compared with placebo, and compared favorably with the market-leading injectable quadrivalent influenza vaccine (QIV) in a Phase 2 challenge trial.